Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $34.61 USD
Change Today +0.03 / 0.09%
Volume 1.5M
HZNP On Other Exchanges
As of 2:07 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/15 - $35.70
52 Week Low
07/29/14 - $7.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HORIZON PHARMA PLC (HZNP)

horizon pharma plc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma plc (HZNP) Details

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). The company also provides RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

605 Employees
Last Reported Date: 05/8/15
Founded in 2005

horizon pharma plc (HZNP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc(NasdaqGS:HZNP) dropped from Russell 2000 Index

Horizon Pharma plc will be removed from Russell 2000 Index

Horizon Pharma plc(NasdaqGS:HZNP) dropped from Russell 3000 Index

Horizon Pharma plc will be removed from Russell 3000 Index.

Horizon Pharma plc Presents at BIO International Convention 2015, Jun-18-2015 09:45 AM

Horizon Pharma plc Presents at BIO International Convention 2015, Jun-18-2015 09:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $34.64 USD +0.06

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $81.35 USD +0.46
Pfizer Inc $33.39 USD -0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at